Cellivery "COVID-19, Final Data Secured from Primate Efficacy Trials"

[Asia Economy Reporter Hyunseok Yoo] Cellivery announced on the 26th that it received results from Southern Research showing that its in-development intrinsic immune regulatory novel coronavirus disease (COVID-19) immune therapeutic 'iCP-NI' suppresses even cytokine storm (immune storm) in a primate model.

The lead researcher for Cellivery's COVID-19 therapeutic development stated, "iCP-NI not only suppresses cytokine storm efficacy in the plasma of COVID-19 infected primates, but also is the first to be exposed to the virus upon COVID-19 infection," adding, "It has been revealed that it suppresses immune storms even in lung tissue, the site where the most severe inflammation occurs, thereby securing definitive evidence as an immune therapeutic new drug that controls systemic inflammation caused by COVID-19 infection and pneumonia in the respiratory tract, the directly infected organ."

The lead researcher emphasized, "We accepted the opinion from Covance, a U.S. clinical contract research organization, that the ongoing COVID-19 primate therapeutic efficacy evaluation test at Southern Research no longer needs to be conducted and that it is sufficient to proceed with clinical trials in the U.S. Therefore, we will not conduct any further monkey tests and will file the clinical trial protocol."

Cellivery CEO Daewoong Cho said, "There is absolutely no difficulty in developing iCP-NI under the emergency use authorization system in the shortest possible time," adding, "Although Remdesivir has received FDA approval, it was developed as an antiviral for Ebola and has not shown particularly effective efficacy against COVID-19."

He stated, "The World Health Organization (WHO) has officially announced that antivirals such as chloroquine, remdesivir, and interferon no longer have therapeutic efficacy against COVID-19," emphasizing, "iCP-NI was developed from the beginning as an immune therapeutic for community infections of pathogenic bacteria and viruses, blocking the expression of a total of 69 types of inflammatory cytokine and chemokine gene groups including subtypes, thereby possessing a precise pharmacological mechanism for suppressing immune storms."